| Number of patients according to ACR/EULAR 2010 RA classification criteria | Number of patients reclassified as high risk | Number of patients reclassified as low risk | Combined sensitivity: RA-2010 criteria + new test | Combined specificity: RA-2010 criteria + new test |
---|---|---|---|---|---|
(A) Add-on test for all patients | |||||
B cell test | Â | Â | Â | 0.85 | 0.69 |
High risk | 243 | 243 | 0 | Â | Â |
Intermediate risk | 263 | 75 (29Â %) | 188 (71Â %) | Â | Â |
Low risk | 46 | 13 (28Â %) | 33 (72Â %) | Â | Â |
IL-6 test | Â | Â | Â | 0.89 | 0.41 |
High risk | 243 | 243 | 0 | Â | Â |
Intermediate risk | 263 | 146 (56Â %) | 117 (44Â %) | Â | Â |
Low risk | 46 | 26 (57Â %) | 20 (43Â %) | Â | Â |
Magnetic resonance imaging | Â | Â | Â | 0.96 | 0.46 |
High risk | 243 | 243 | 0 | Â | Â |
Intermediate risk | 263 | 154 (59Â %) | 109 (41Â %) | Â | Â |
Low risk | 46 | 26 (59Â %) | 20 (41Â %) | Â | Â |
Genetic assay test | Â | Â | Â | 0.77 | 0.66 |
High risk | 243 | 243 | 0 | Â | Â |
Intermediate risk | 263 | 64 (24Â %) | 199 (76Â %) | Â | Â |
Low risk | 46 | 11 (24Â %) | 35 (76Â %) | Â | Â |
(B) Add-on test for intermediate-risk patients | |||||
B cell test | Â | Â | Â | 0.81 | 0.71 |
High-risk | 243 | 243 | 0 | Â | Â |
Intermediate risk | 263 | 75 (29Â %) | 188 (71Â %) | Â | Â |
Low risk | 46 | 0 | 46 | Â | Â |
IL-6 test | Â | Â | Â | 0.85 | 0.46 |
High risk | 243 | 243 | 0 | Â | Â |
Intermediate risk | 263 | 146 (56Â %) | 117 (44Â %) | Â | Â |
Low risk | 46 | 0 | 46 | Â | Â |
MRI | Â | Â | Â | 0.91 | 0.51 |
High risk | 243 | 243 | 0 | Â | Â |
Intermediate risk | 263 | 154 (59Â %) | 109 (41Â %) | Â | Â |
Low risk | 46 | 0 | 46 | Â | Â |
Genetic assay test | Â | Â | Â | 0.75 | 0.67 |
High risk | 243 | 243 | 0 | Â | Â |
Intermediate risk | 263 | 64 (24Â %) | 199 (76Â %) | Â | Â |
Low risk | 46 | 0 | 46 | Â | Â |